{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Dr.+Falk+Pharma+GmbH",
    "query": {
      "sponsor": "Dr. Falk Pharma GmbH"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T23:10:57.010Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03844932",
      "title": "A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "ST-0529",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sublimity Therapeutics Holdco Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 235,
      "start_date": "2019-01-24",
      "completion_date": "2021-04-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-07",
      "last_synced_at": "2026-10-10T23:10:57.010Z",
      "location_count": 8,
      "location_summary": "Palm Springs, California • Largo, Florida • New Port Richey, Florida + 4 more",
      "locations": [
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03844932"
    },
    {
      "nct_id": "NCT05621811",
      "title": "Different Doses of Naronapride vs. Placebo in Gastroparesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroparesis"
      ],
      "interventions": [
        {
          "name": "Naronapride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Falk Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 328,
      "start_date": "2023-01-03",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-10T23:10:57.010Z",
      "location_count": 23,
      "location_summary": "Chula Vista, California • Lomita, California • Clearwater, Florida + 18 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621811"
    },
    {
      "nct_id": "NCT06596252",
      "title": "Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Falk Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 308,
      "start_date": "2021-05-21",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-10T23:10:57.010Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06596252"
    },
    {
      "nct_id": "NCT01038739",
      "title": "Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diverticulitis"
      ],
      "interventions": [
        {
          "name": "Mesalazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Falk Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 330,
      "start_date": "2010-01",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-10-10T23:10:57.010Z",
      "location_count": 1,
      "location_summary": "New Smyrna Beach, Florida",
      "locations": [
        {
          "city": "New Smyrna Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01038739"
    }
  ]
}